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Reduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-
protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid eﬀects of statins. However, the
decrease of LDL-cholesterol, the reduction of inﬂammation biomarkers and even the atheroregresion, as surrogate eﬀects to the
mechanismsofaction ofstatins would be irrelevant if notaccompanied by a signiﬁcantdecrease inthe incidence ofcardiovascular
events. Statins like no other pharmacologicalgroup have proven to reduce the incidence of cardiovascular events and prolong life
in any clinical scenario. This article review the basic and clinical evidence that support a new indication for HMG-CoA reductase
inhibitors “pharmacologicalmyocardial preconditioning before anticipated ischemia” or hyperacute use of statinsin subjects with
any coronary syndrome eligible for elective, semi-urgent or primary percutaneous coronary intervention: ARMYDA-Original,
NAPLES I-II, ARMYDA-ACS, ARMYDA-RECAPTURE, Non-STEMI-Korean, Korean-STEMI trials.
1.Introduction
The inhibitors of Hydroxy Methyl Glutaryl-Coenzyme A
Reductase (I-HMG-CoA-R) or statins have become the
cornerstone of drug therapy that aimed at reducing cardio-
vascular risk. Statins are the pharmacological group with
the highest reduction power of the serum LDL cholesterol
concentration,apartfromotherlipidandpleiotropicactions.
Therefore, their therapeutic eﬃcacy can be explained if
we remember that LDL cholesterol modiﬁed by oxidation
becomes an epitope, which provokes along with other
endothelial-vascular lesion factors, a pathological sequence
with atherosis, endothelial activation-dysfunction lesion,
atherosclerosis, and atherothrombosis. Thus, statins have
become the most important pharmacological weapon for
cardiovascular risk reduction when associated to atheroscle-
rosis.
This paper reviews the most important pharmacological
properties of statins, starting with new information on the
mechanisms of action and eﬀects that explain the reduction
of LDL cholesterol concentration in serum, as well as
nonlipid or pleiotropic eﬀects. These basic concepts will be
the foundations that will lead us to a better understanding
of the impact of statins in new clinical applications, specially
focusing on the role they play as reducers of Percutaneous
Coronary Intervention (PCI) complications in individuals
with stable and unstable coronary syndromes with and
without ST segment elevation.
2.Statins:Mechanism ofAction
The ﬁrst statin extracted from Penicillium citrinum was
discovered by Dr. Akira Endo in the 70s. Based on the
knowledge of cholesterol synthesis from acyl and acetyl-
CoA, Endo showed that compactin when competing with
the HMG-CoA was an inhibitor of the enzyme that regu-
lates cholesterol synthesis. Statins speciﬁcally compete with2 International Journal of Hypertension
HMG-CoA for the catalytic site of its reductase (HMG-
CoA-R). This competition inhibits the metabolic pathway
of HMG-CoA into mevalonate, a precursor molecule for
the synthesis of cholesterol and other molecules such as the
isoprenoids, Farnesyl and Geranyl Pyrophosphates [1, 2].
Endo’s discovery was complemented and made clinically
relevant by the studies of Joseph Goldstein and Michael
Brown. Both researchers discovered the cellular receptor for
LDL cholesterol (LDL-R) and described three concepts that
would revolutionize medicine. Such concepts gave them a
Nobel Prize in 1985 [3]. These “classical” concepts of and
new data on the mobilization of intracellular cholesterol are
presented as follows (see Figure 1).
(a) Receptor-Mediated Endocytosis. Each LDL macromole-
cule contains an average of 1500 molecules of cholesteryl
ester; it gets into cells through the existence of LDL-R. These
receptors are glycoproteins with 5 domains, embedded in
convex structures of the cell membrane, formed by clathrin
protein, and called “clathrin-coated pits.” These structures
serve as gathering places for cell surface receptors aimed at
endocytosis. Once the LDL cholesterol is taken up by the
LDL-R,anendocyticvesiclecalledendosomeorreceptosome
is formed. Within the cell the LDL-R leaves the endosome
and returns to the cell membrane; this dissociation is favored
by a decrease in pH within the endosome. The LDL is
transferred from the endosomes to the lysosomes and within
them; both lipids and apoproteins are hydrolyzed, the ﬁrst
one into nonesteriﬁed cholesterol and the second into amino
acids [3–5].
(b) Self-Regulation of the Receptor. Nonesteriﬁed cholesterol
due to its being hydrophobic cannot move freely within
the cell cytoplasm. The transport means of nonesteriﬁed
cholesterol from the lysosome to the cell membranes was
recently described by Brown and Goldstein and has been
called “hydrophobic handoﬀ mechanism.” In this process
proteins Niemann Pick 2 and 1 form a “hydrophobic core”
that contains and carries the nonesteriﬁed cholesterol. The
concentration of cholesterol in cell membranes, including
the membrane of the Sarcoplasmic Reticulum/Golgi Appa-
ratussystem, is the signal to regulate the connection between
the transcription factor, Sterol Regulatory Element Binding
Protein (SREBP), and its anchor protein SREBP-Cleavage
Activating Protein (SCAP). Cytoplasmic sequestration of
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other enzymes involved in cholesterol synthesis, especially
HMG-CoA-R.The higher theconcentration of cholesterol in
cell membranes, the greater the inhibition of the synthesis
of LDL-R. Free nonesteriﬁed cholesterol in the cytoplasm
is reesteriﬁed by Acyl-CoA Cholesterol Acyl Transferase
1 (ACAT1) and then it can be integrated to the cellular
metabolism [3–6].
(c) Recycling of the Receptor. The LDL-R plays an inside-
out cell cycle every 10 minutes, so each LDL-R makes more
than hundred cycles during its average 20-hour life. The cell
cycle of the LDL-R can be interrupted by the action of the
recently discovered Proprotein Convertase Subtilisin Kexin
type 9 (PCSK9)[7].
Thus, by inhibiting the HMG-CoA-R, the mechanisms
that allow statins to reduce concentrations of cholesterol
in serum are the following: (a) reduction of cholesterol
hepatic synthesis and therefore a reduction in the synthesis
of VLDL, an IDL and LDL precursor; (b) reduction in
the concentration of cholesterol in the membranes of
the hepatocyte and increased transcription, synthesis and
expression of LDL-R with an aﬃnity for IDL (in apo-E) and
LDL(inapo-B100);(c)increase inhepaticuptakeofIDLand
LDL and cholesterol hepatobiliary elimination [8, 9]. The
cholesterol-lowering power ofstatins is directly related to the
numberoflinkstheyestablishwiththecatalyticsiteofHMG-
CoA-R; atorvastatin establishes 8 links while rosuvastatin 9,
and therefore the inhibition coeﬃcients of 50% (IC-50) of
the enzymatic action of HMG-CoA-R are of 5.4 and 8.2
nanomoles, respectively [8–12].
3.Statins—EffectsonCholesterol,
BiomarkersofInﬂammation,and Myocyte
Protection:Cholesterol Reduction
The average reduction of cholesterol in serum is a function
of the statin and its dosage; 10mg of atorvastatin or
rosuvastatin 5mg achieve an average reduction of 35% in
the baseline value of LDL cholesterol, while the maximum
therapeutic doses 80mg and 40mg, respectively, produce
an average reduction of 50% and 55%. This eﬀect is
independent of the hydrophilicity (facilitated diﬀusion by
Organic Anion Transporters of Polypeptides or OATP) or
lipophilicity(direct diﬀusion)ofthestatin. These dataallows
us to calculate the optimal therapeutic dose of a statin
according to baseline LDL cholesterol, the goal regarding the
cardiovascular risk level and the treatment gap [13–15].
Reduction in Inﬂammation Biomarkers. Statins not only
reduce the concentration of LDL cholesterol in serum, as
mentioned above, inhibition of the synthesis of mevalonate
by statins also blocks the synthesis of isoprenoids (Farne-
syl and Geranyl Pyrophosphates). In the phenomenon of
endothelial activation, isoprenoids play a very important
role [16, 17]; in endothelial cells, binding of oxidized LDL
cholesterol to its LOX Receptor activates the expression
of its inﬂammatory phenotype; during such process, the
intracellular switch is the isoprenylation of small G type
proteins (smgs). These proteins are called G for their
guanosine content, when nonactive, smgs are “ﬂoating” in
the cellular cytoplasm linked to Guanosine Diphosphate
(GDP), and its activation depends on the presence of
isoprenoids and the Guanosine Exchange Factor (GEF).
With the participation of both molecules, the GDP acquires
a phosphate group and becomes Guanosine Triphosphate
(GTP); thus, the inactive smgs acquire the characteristic of
GTPases, migrate, anchor themselves to the cell membrane,
and exert their phosphorylating action on various substrates
for activation of multiple enzymatic cascades. GTPases are
divided into several enzyme families, the most important areInternational Journal of Hypertension 3
LDL
Ce
Endosome
Ce
Ce
Handoﬀ
NP2 NP1 C
Hydrophobic transport
Recycling
Lysosome
Ce
Lysis
AA
AA
Deesteriﬁcation
Reesteriﬁcation
ACAT1
C
RES-GA
SCAP-SREBP
Synthesis inhibition
LDL receptor
Clathrin-coated pits with LDLreceptor
1
2
3
4
5
B100
B100
B100
Figure 1: Regulation of LDL-R in 5 steps. Step 1. The LDL is recognized in apo-B100 by the LDL-R located in the membrane structures
“clathrin-coated pits.” Step 2. It forms an endocytic vesicle or endosome containing LDL and LDL-R, the LDL-R is dissociated through
lowering of the pH within the endosome, and the LDL is transferred to the lysosomes. Step 3. In lysosomes, apo-B100 is hydrolyzed into
amino acids and cholesteryl ester is deesteriﬁed by enzymatic hydrolysis. Step 4. Nonesteriﬁed cholesterol (hydrophobic) is transported to
the cell membranes by the “hydrophobic handoﬀ mechanism”; in this mechanism Niemann Pick 2 and 1 proteins form a hydrophobic
core containing nonesteriﬁed cholesterol. Step 5. Nonesteriﬁed cholesterol is transferred by the binomial NP2-NP1 to cell membranes, its
concentration in the Sarcoplasmic Reticulum/Golgi Apparatus membranes is the signal that inhibits the dissociation of SCAP-SREBP and
thus blocks the synthesis of LDL-R.
the so-called Ras, Rho, and Rab, each stimulating diﬀerent
cellular processes involved in the inﬂammatory process (e.g.,
the smg Ras modulate cell division and growth, the smg
Rho proteins activate the cell cytoskeleton, and the smg
Rabregulateintracellularvesicularmovement)(see Figure2)
[18, 19].
Thus, inhibition of isoprenoid synthesis by statins
reduces isoprenylation of smgs proteins and blocks in
diﬀerent degrees the inﬂammatory response initiated by
oxidized LDL cholesterol binding to LOX-R. Inﬂammatory
endothelial activation initiated by the binding of other
ligands to their receptors (e.g., angiotensin II to AT1-R or
AGEs to RAGEs) is also generated from a process of smgs
and G proteins isoprenylation; this explains why the anti-
inﬂammatory eﬀect of statins is not proportional to the
reduction of LDL cholesterol; its anti-inﬂammatory capacity
goes beyond this fact due to its potential to inhibit the
switch of inﬂammatory endothelial activation, regardless of
the stimulus [20, 21].
Multiple in vitro evidence has been published, in
vivo in experimental animals and in vivo in individuals
with atherosclerosis such evidence has shown that statins
attenuate vascular endothelial inﬂammatory process of
atherosclerosis itself. This endothelium-vascular inﬂamma-
tory attenuation is independent but synergistic with LDL
cholesterol reduction. The following are among the most
important pieces of evidence. Dr. Jain’s team at Harvard
proved in vitro that statins promote on endothelial cells the
expression of Kruppel-Like Factor 2 (KLF2), transcription
factor for the synthesis of eNOS and thrombomodulin
[22]. Thus, statins stimulate the synthesis of eNOS, an
enzyme responsible for the production of nitric oxide,
which among its many actions promotes on the endothelial
cell the intracytoplasmic sequestration of the transcription
factor NFκB (group of “master” transcription factors of
the inﬂammatory response). The translation in vivo, in
the experimental animal, of the anti-inﬂammatory eﬀect of
statins has been published by several researchers. For exam-
ple, in the animal model of aortocoronary atherosclerosis in
mice, when blindly compared with placebo, statins decrease
“acutely” the monocyte inﬁltration into atherosclerotic aor-
tocoronary areas [23]. This phenomenon is equivalent to
the in vivo demonstration in humans of “acute” reduction
of the inﬂammatory activity in aortas with atherosclerosis
in subjects treated with statins. By using 18FDG-PET, it
has been shown that the administration of atorvastatin4 International Journal of Hypertension
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Figure 2: Statins reduce cholesterol, and isoprenoids synthesis. The statins inhibit HMG-CoA-R and block the synthesis of mevalonate,
cholesterol,andisoprenoids.In thehepatocyte, the reduction in cholesterol synthesisdetermines a reduction in VLDL synthesisandincrease
in the synthesis of LDL-R; thus, the reduced production of VLDL, IDL, and LDL and increased elimination of circulating IDL, and LDL,
explain the reduction in LDL concentration. In the endothelial cells the reduction in the synthesis of isoprenoids determines a reduction of
the inﬂammatory response mediated by inactivation of smgs from diﬀerent families (Rho, Ras, Rab).
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Figure 3: Statins, mechanisms, and myocyte-protective eﬀects. Statins increase the expression of KLF2 and eNOS synthesis and also increase
the activation of eNOS and nitric oxide production. In the myocyte the activation of AMPK increases the income and energy substrate
utilization, as well as the production of ATP.
signiﬁcantly reduced inﬂammatory activity in human aortas
with atherosclerosis; this change in inﬂammatory activity
occurs within days and was not associated with signiﬁcant
changes in the concentration of LDL cholesterol in serum
[24].
Myocyte Protection. Statins in experimenting animals have
shown a myocyte-protective eﬀect, this eﬀect is independent
of LDL-cholesterol reduction and anti-inﬂammatory eﬀect
and have been associated with the activation of two cellular
protectiveenzyme systems, theReperfusionIschemic Salvage
Kinases pathway (RISK pathway) and the AMP-activated
Kinase (see Figure 3)( A M P K )[ 25–30].
RISK Pathway. Nitric oxide production by activation of
enzymatic cascade PI3Kinase-Akt2-eNOS is a physiologicalInternational Journal of Hypertension 5
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Figure 4: Statins and recapture of the RISK pathway. This
modiﬁed graphic of Mensah’s work, shows how the quotient
(necrosis/ischemia) is similar in rats treated for 1 or 2 weeks with
methylcellulose (red bars) or atorvastatin (blue bars). This loss
of myocyte-protective eﬀect is “recaptured” signiﬁcantly with the
reload of atorvastatin(green bars).
process of cell protection against ischemia and statins have
been proven to potentiate this process. However, Yellon and
his colleagues have shown in experimental animals that
“chronic” experimental administration of statins prevents
the production of nitric oxide through RISK pathway.
This inhibition is due to the overexpression of the Phos-
phatase Tensin (PTEN) with an antagonistic action towards
PI3Kinase. This blockade of the RISK pathway can be
recaptured with the administration of a statin reload [31].
Mensah demonstrated in experimental rats subjected to
myocardial ischemia and postischemia reperfusion that the
quotient (myocardial necrosis/ischemia) after reperfusion
was signiﬁcantly reduced by administration prior to the
ischemia of an acute dose (day 1 and day 3) of atorvastatin.
This myocyte-protective eﬀect was canceled when the statin
was administered for longer periods (1 and 2 weeks) before
induction of myocardial ischemia. The cancellation of the
myocyte-protective eﬀect was associated with a signiﬁcant
increase in the concentration of PTEN. The most important
ﬁnding of this series of experiments was the evidence that, in
animals treated for 1 or 2 weeks with atorvastatin, the reload
of atorvastatin in day 1 signiﬁcantly reduced the quotient
(myocardial necrosis/ischemia), which, means that it “recap-
tured the RISK pathway.” (see Figure 4) The hypothesis is
thatstatins reloadmanages toinhibittheexpressionofPTEN
and enhances the expression of PI3Kinase-Akt2-eNOS with
increased production of nitric oxide [31]. This evidences
provided the rationale and name of the study ARMYDA-
RECAPTURE analyzed as follow.
AMPKinase. This enzyme is considered the energetic
switch of the ischemic, cell. In the ischemic cell there
is an inversion of the quotient ATP/AMP by increased
cytoplasmic concentration of AMP (ADP + ADP = 1A T P
+ 1 AMP). The AMP increase is the signal that activates
the gamma subunit of the AMPK and initiates multiple
phosphorylation substrates (AMPK-kinases). Among the
substrates activated by AMPK are the glucose transporters
(GLUT4), fatty acid transporters (CD36) and key enzymes
of the pathways of glycolysis and beta-oxidation. Thus
activation of AMPK increases cellular entry, the use of
glucose and free fatty acids, as well as the production of ATP.
There is much evidence that molecules such as adiponectin,
metformin, and statins are indirect AMPK activators,
thereby exercising a myocyte-protective eﬀect, especially in
scenarios of myocardial ischemia [28]. To summarize, the
RISK pathway and the AMPK are activated by statins in
an LDL-independent manner. The RISK pathway increases
nitric oxideproduction and AMPK increases cellular income
and utilization of glucose and fatty acids which optimizes
the energy eﬃciency of the ischemic cell [25–31].
4.Statins:ClinicalEffectsinPercutaneous
CoronaryIntervention(HyperacuteUse)
Based on observational studies, most notably Chang’s [32]
randomized studies were designed and provided solid evi-
dence resulting in new options for therapeutic use of statins
in subjects undergoing elective, semiurgent (12–48 hours
of “interventional window”), and primary Percutaneous
Coronary Intervention (PCI). The reduction in the risk of
Myocardial Infarction-PCI associated (MI-PCI associated)
with a statin load prior to PCI is undoubtedly an important
therapeuticbeneﬁtthat ischanging thetherapeuticapproach
on the hemodynamics prelude, which will probably give
statins a new indication (pharmacologic preconditioning
against anticipated myocardial ischemia)[ 33–42]. The Ital-
ian group led by Germano Di Sciascio began, with its
publication in 2004, the series of formal clinical studies
supporting the concept of myocardial preconditioning by
statin against anticipated myocardial ischemia. This series
of studies include the following: ARMYDA-Original [34],
ARMYDA-CAMs [35], NAPLES I-II [36, 37], ARMYDA-
ACS [38], ARMYDA-RECAPTURE [39], ARMYDA-AMI
[40],stillunderrecruitmentstage,andtherecentlypublished
Koreans studies on Non-STEMI [41]a n dS t a t i n - S T E M I[ 42]
(see Table 1).
Before addressing the analysis of these studies, it is
important to review the deﬁnition of MI-PCI associated,
its frequency, and prognosis implications. Since 2007, the
diagnosis criteria for MI-PCI associated is 3 times greater
than the normal maximum value of CPK-MB and/or
troponins (before 2007 the criteria was 2 times more)
[43]. The MI-PCI associated is common, its incidence
has been reported as high as 70%, and its pathogenesis
involves several factors: some of the most important are the
endothelial-vascular size and condition of the compromised
territory, the spontaneous microembolization, as well as the
microembolization induced by the triad catheter-balloon-
Stent with distally compromised microcirculation, collateral
circulation, and myocardial ability to respond to trans6 International Journal of Hypertension
Table 1: Randomized trials with statins in percutaneous coronary intervention. This table is a summary of the 8 randomized trials (versus
placebo or versus control groups) published with statins in individuals under PCI. All studies except Vaselka’s have shown positive results
for the use of statins prior to PCI. The results in individuals with elevated CRP before PCI (NAPLES II) and in individuals with ACS
(ARMYDA-ACS y ARMYDA-RECAPTURE, ACS soubgroup), are particularly favorable. MI-PCI-A: Myocardial Infarction-PCI associated.
MACE: Mayor Adverse Cardiovascular Events. MRI: Myocardial Reperfusion Indicators.
Trial Interventional scenario Treatment Primary end point
ARMYDA-Original
N 153 naive (76/77) Non-ACS Atorvastatin versus placebo 40mg/7
days pre-PCI
↓ MI-PCI-A. CPK-MB > 2x ULN
05.0% versus 18.0% (P = .025)
NAPLES I
N 451 naive (226/225) Non-ACS Various statins versus control
Diﬀerent doses >72hr pre-PCI
↓ MI-PCI-A. CPK-MB > 3x ULN
08.0% versus 15.6% (P = .012)
NAPLES II
N 668 naive (338/330) Non-ACS Atorvastatin versus control
80mg/24hr pre-PCI
↓ MI-PCI-A. CPK-MB > 3x ULN
09.5% versus 15.8% (P = .014)
↓ MI-PCI-A. CPK-MB > 3x ULN
04.6% versus 16.5% (P = .016)
(subgroup CRP > 6mg/lt)
ARMYDA-ACS
N 171 naive (85/86) Non-STEMI ACS Atorvastatin versus placebo
120mg/12hr pre-PCI
↓ MACE day 30. 05.0% versus
17.0% (P = .01)
↓ MI-PCI-A. CPK-MB > 2x ULN
0.5% versus 15.0% (P = .04)
ARMYDA-REC
N 383 preTx (192/191)
Non-STEMI ACS
47%
Non-ACS
53%
Atorvastatin versus placebo
120mg/12hr pre-PCI
↓ MACE day 30. 03.7% versus
09.4% (P = .037).
↓ MACEs day 30. 03.3% versus
14.8% (P = .015) (subgroup ACS)
Non-STEMI Korean
N 445 naive (220/225) Non-STEMI ACS Rosuvastatin versus control
40mg/16hr pre-PCI
↓ MI-PCI-A. CPK-MB > 2x ULN.
05.8% versus 11.4% (P = .035).
STEMI Korean
N 171 naive (86/85) STEMI ACS Atorvastatin high versus low dose
80mg versus 10mg in primary PCI
↓ MACE day 30. 05.8% versus
10.6% (P = .26)
↑ MRIs min 90 after PCI. All
indicators P<. 05
Vaselka
N 200 naive (100/100) Non-ACS Atorvastatin versus Control
80mg/48hr pre-PCI
↓ MI-PCI-A. CPK-MB > 3x ULN
10.0% versus 12.0% (P = .065)
and postreperfusion ischemia (myocardial preconditioning)
[44]. The MI-PCI associated, even if it is only enzymatic, is
associated with deterioration in the prognosis; even when
the importance of MI-PCI associated has been minimized,
the morbidity and mortality in the medium and long term
are directly proportional to the magnitude of PCI-related
enzyme increase [45].
5.ClinicalStudiesinPercutaneous
CoronaryIntervention
5.1. ARMYDA-Original. Aware of observational evidence,
Germano Di Sciascio leading the group Romano ARMYDA
designed the Original ARMYDA study. This pivotal study
showed that individuals with stable coronary syndromes,
statin-naive, and with indication of elective coronary angio-
plasty, who received 40mg of atorvastatin a day, seven days
before PCI, underwent a signiﬁcant reduction of the relative
riskofMI-PCIassociated(CPK-MB>2xULN,2004criteria)
as compared to those treated with placebo; 18% in the
placebo group versus 5% in the atorvastatin with P = .025
(see Figure 5).
5.2. ARMYDA-CAMs. The substudy ARMYDA-CAMs (Cell
Adhesion Molecules) provided a mechanistic explanation
for the overall study results of the ARMYDA-Original
study. Patty showed that in the arm treated with 40mg of
atorvastatin a day for seven days before PCI, the increase
in adhesion molecules (E-selectin and ICAM-1) 24 hours
after intervention, was limited signiﬁcantly (P = .0001)
[35]. This ﬁnding reﬂects a facet of the anti-inﬂammatory
eﬀect of statins, which while inhibiting the expression of
the transcription factors likeNFκB,decrease endothelialcells
synthesis of these adhesion molecules [16–19]( s e eF i g u r e6).
5.3. NAPLES I-II. Carlo Briguori, inspired by the results of
the pilot study (NAPLES I) [36] and the already mentioned
ARMYDA-Original, developed and published in 2009 the
results of NAPLES II trial. This relevant study showed that
individuals with stable coronary syndromes, statin-na¨ ıve,
and with indication of elective coronary angioplasty, who
received 80mg of atorvastatin a day, 24 hours before PCI,
underwent a signiﬁcant reduction of the relative risk of
MI-PCI associated (CPK-MB > 3x ULN, 2007 criterion) as
comparedtothosetreatedwithplacebo,15.8%intheplacebo
group versus 9.5% in the atorvastatin group with P = .014.
With this study, the Naples-Milan group suggested that it
is possible to shorten the therapeutic window of the statin
load from 7 days to 24 hours. The therapeutic result of the
statins load was outstanding in the subgroup with positiveInternational Journal of Hypertension 7
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Figure 5: ARMYDA-Original study. This modiﬁed graphic of
the ARMYDA-Original study (Vincenso Pasceri as ﬁrst author)
demonstrated for the ﬁrst time as a randomized study the favorable
eﬀect of statins before PCI. In individuals with stable coronary syn-
dromes, statin-na¨ ıve, undergoing elective PCI, the administration
of atorvastatin 40mg/7 days before PCI signiﬁcantly reduces the
incidenceofMI-PCI associated(CPK-MB>2xULN,2004criteria).
The MI-PCI associated was 18% in the placebo group versus 5% in
the atorvastatin group with P = .025.
CRP by latex (CRP > 6mg/L) before PCI; in this subgroup,
the incidence of MI-PCI associated (CPK-MB > 3x ULN,
2007 criterion) was 16.5% in the control group compared
with 4.6% in the atorvastatin group with P = .016 [37]( s e e
Figure 7).
The results of previous studies in individuals with stable
coronary syndromes, motivated the design of ARMYDA-
ACS and later ARMYDA-RECAPTURE, the ﬁrst in statin-
naive individuals and the second in people with chronic
statin treatment. These are the two recent studies pub-
lished by the ARMYDA group, pending the publication of
ARMYDA-AMI (Acute Myocardial Infarction).
5.4. ARMYDA-ACS. ARMYDA-ACS study showed that, in
individuals with Acute Coronary Syndromes, without ST-
segment elevation, statin-na¨ ıve, and with semiurgent indi-
cation of percutaneous coronary angioplasty, who were
administrated 120mg of atorvastatin divided into two doses,
ad o s eo f8 0m gt w e l v eh o u r sb e f o r ea n da n o t h e r4 0m gt w o
hours before PCI, there was a signiﬁcant reduction in the
incidenceofMACEsor MajorAdverseCardiovascularEvents
(myocardial infarction, re intervention or cardiovascular
death), as compared to those treated with placebo. The
relative risk reduction of MACEs reached 88%; 17% in the
placebo group versus 5% in the atorvastatin group with P =
0.01. This reduction in MACEs was dominated by a decrease
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Figure 6: ARMYDA-CAMs study. This modiﬁed graphic of the
ARMYDA-CAMs study showed that, in a preselected subgroup
or the ARMYDA-Original study, in individuals with stable coro-
nary syndromes, statin-na¨ ıve, and undergoing elective PCI, the
administrationofatorvastatin40mg/7daysbefore PCIsigniﬁcantly
reduced the percentage of elevation 24 hours after PCI of ICAM
and E-selectin. This reduction was not observed with VCAM (not
shown in the graphic).
in MI-PCI associated (CPK-MB > 2x ULN, 2004 criterion),
15% in the placebo group versus 5% in the atorvastatin
group with P = .04 [38].
5.5. ARMYDA-RECAPTURE. The ARMYDA-RECAPTURE
or RELOAD raised the hypothesis that the recapture of RISK
pathway observed in experimental animals could be repro-
duced in the hospital. This study included individuals with
an indication of PCI, who evolved into a stable or unstable
coronary syndrome without ST-segment elevation, when
chronically treated with statins and LDL < 100mg/dl. In a
design similar to ARMYDA-ACS, this study demonstrated
that administration of atorvastatin 120mg, divided into two
doses, a dose of 80mg twelve hours before and another
of 40mg two hours before PCI, signiﬁcantly reduced the
incidence of MACEs (myocardial infarction, reintervention,
or cardiovascular death) as compared with those treated
with placebo; 9.4% in the placebo group versus 3.7% in
the atorvastatin group with P = .037. This reduction in
MACEs was dominated by a decrease in MI-PCI associated
(CPK-MB > 3x ULN, 2007 criterion), 8.9% in the placebo
group versus3.7%in theatorvastatin group. The therapeutic
beneﬁt reached its maximum in the subgroup with unstable
coronary syndromes, with an incidence of MACEs greater
than 14.8% in the placebo group versus 3.3% in the
atorvastatin group with P = .015, and a Number Needed to8 International Journal of Hypertension
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Figure 7: NAPLES II Study. This modiﬁed graphic of the NAPLES II study, conﬁrmed with a randomized study, as compared to a control
group, the favorable eﬀect of statins before PCI. In individuals with stable coronary syndromes, statin-naive undergoing elective PCI, the
administration of atorvastatin 80mg/24 hours before PCI signiﬁcantly reduces the incidence of MI-PCI associated (CPK-MB > 3x ULN,
2007 criteria). As can be seen, the beneﬁt was especially signiﬁcant in the subgroup of individuals with CRP > 6mg/LbeforePCI,inthis
subgroup the incidence of MI-PCI associated was 16.5% in the control group versus 4.6% in the atorvastatingroup with P = .016.
Treat (NNT)of 9 individuals to avoid an MACE, an excellent
cost-beneﬁt relation [39]( s e eF i g u r e8).
5.6. Non-STEMI and Statin-STEMI Korean Studies. The
Korean group led by Ho Yun Kyeong reproduced the results
of ARMYDA-ACS. The author used 40mg of rosuvastatin
a day administered an average of 16 hours before PCI,
compared with a control group, in individuals with Non-
STEMIacutecoronary syndromes, and reported asigniﬁcant
reduction in the incidence of MI-PCI associated (CPK-MB
> 2x ULN, 2004 criterion), 11.4% in placebo group versus
5.8% in the rosuvastatin group with P = .035 [41].
In early 2010 they were also published by a Korean group
(the ﬁrst author was Kim Jung-Sum), the results of Statin-
STEMI study which explored the eﬀect of an 80mg dose
versus 10mg dose of atorvastatin in subjects with STEMI
undergoing primary coronary angioplasty. In this study, the
primary objective (MACEs at day 30 after PCI) was not
positive, but still it did show a trend towards the beneﬁt
with the high dose of atorvastatin; MACEs at day 30 after
PCI 5.8% in the 80mg atorvastatin group versus 10.6% in
the 10mg atorvastatin group with P = .026. This result
is probably explained by the size of the sample (171 indi-
viduals), the low dose of atorvastatin after PCI (10mg/day)
and/or the short followup time. However, in the secondary
objective (Myocardial Reperfusion Indicators or MRI), there
actually was a signiﬁcant diﬀerence favoring the high dose
of atorvastatin; corrected TIMI Frame Count (cTFC) 29.6
versus 34.1 with P = .01; completed STResolution (cSTR)
61.8 versus 50.6 with P = .01; and Myocardial Blush Grade
(MBG) 2.2 versus 1.9 with P = .02 [42]( s e eF i g u r e9).
As a whole, the results of the studies mentioned, all
performed in a quintessential endothelial-vascular inﬂam-
matory environment, strengthen the presence and impor-
tance of nonlipid eﬀects of statins. These results not only
support the anti-inﬂammatory potential of statins due to
the eﬀect of “endothelial passivation” but also highlight
the myocyte-protective actions of these drugs. From a
clinical-therapeutic perspective, the evidence presented here
represents a new indication for statins, which although not
yet reﬂected in the guidelines, is changing the therapeutic
behavior of Clinical and Interventional Cardiologists at the
hemodynamics prelude,because as StephenEllis wrote in his
editorial for the ARMYDA-RECAPTURE study, “the beneﬁt
of statins in PCI, is virtually indisputable and is associated with
pleiotropic actions”[ 29].
6.Statinsand PCI:Abstract
After compactin, discovered by Akira Endo in the 70s, statins
have shown that, when competing with the HMG-CoA by
the catalytic site of its reductase, they very eﬀectively inhibit
the synthesis of mevalonate, cholesterol, and isoprenoids
[1]. This metabolic block favors the reduction in theInternational Journal of Hypertension 9
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Figure 8: ARMYDA-RECAPTURE study. This modiﬁed graphic of the ARMYDA-RELOAD (RECAPTURE) study, showed with a
randomized design, as compared to patients treated with placebo, the recapture eﬀect of statins. In individuals with stable and unstable
coronary syndromes, chronically treated with statins and LDL <100mg/dl, who underwent elective or semiurgent PCI, the administration
of 120mg of atorvastatin before PCI signiﬁcantly reduces the incidence of MACEs on day 30 after PCI. This beneﬁt was very signiﬁcant in
the subgroup of individuals with unstable coronary syndromes, with an MACEs incidence of 14.8% in the placebo group versus 3.3% in the
atorvastatingroup with P = .015.
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atorvastatin before primary PCI on the Myocardial Reperfusion
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with STEMI.
cellular synthesis and concentration of cholesterol in the
membranes of hepatocytes, this condition being the signal
that upregulates the synthesis, expression, and activity of
LDL-R discovered by Brown and Goldstein. The activity of
the LDL-R increases the uptake and hepatobiliary elimina-
tion of circulating cholesterol this along with the reduction
inVLDLsynthesis;themechanisms thatexplainstheeﬀective
(35%to50%)reductioninLDL-cholesterolinserum[2–15].
The block of Farnesyl and Geranyl Pyrophosphates synthesis
attenuates isoprenylation and activation of GTPases (Ras,
Rho and Rab), inhibiting at various degrees, disregarding
the external stimulus, the activity of endothelium-vascular
inﬂammatory enzyme cascades [16–24]. Direct activation
of PI3K-Akt2-eNOS and indirect activation of AMPK
optimizes the supply, uptake and metabolism of energy
substrates in the ischemic myocardial cell [25–31]. Thus,
the reduction of LDL-cholesterol concentration in serum,
blocking the isoprenylation of GTPases and the activation
of myocyte-protective enzyme systems are three mechanisms
that currently explain the lipid and nonlipid eﬀects of statins
[1–31].
As commented in the body of this paper, the decrease of
LDL cholesterol, the reduction of inﬂammation biomarkers
and even the atheroregression [46–49], as surrogate eﬀects
to the mechanisms of action of statins would be irrelevant if
not accompanied by a signiﬁcant decrease in theincidence of
cardiovascular events. Statins like no other pharmacological
group have proven to reduce the incidence of cardiovascular
eventsand prolong life in any clinicalscenario: in individuals10 International Journal of Hypertension
of medium or high risk, with no clinical evidence of
cardiovascular disease (CTT meta-analysis andASCOT-LLA,
CARDS,JUPITERtrials) [50–54];inindividualswithclinical
cardiovascular disease, regardless of its manifestation, be
it stable coronary syndrome (TNT trial) [55–57], unstable
coronary syndrome (MIRACL, PROVE-IT trial) [58–63],
carotid vertebral (SPARCL trial) [64]; in subjects with
any coronary syndrome eligible for elective, semiurgent, or
primary PCI (ARMYDA-Original, NAPLES I-II, ARMYDA-
ACS-RECAPTURE ARMYDA, Non-STEMI-Korean, STEMI
Korean trials) [34–42].
Furthermore, the beneﬁt of statins is being studied in
other scenarios dominated by inﬂammation with positive
results in rheumatic mitral valve disease [65]. In addition
to this, new lines of research are being explored on the
eﬀect of statins on endothelial regeneration [66–68]. Finally,
inhibitionatpre- andposttranslationallevelsofthePCSK9is
an option that poses an interesting future in the treatment of
high LDL cholesterol [69]. Obviously the treatment of other
atherogenic lipid fractions (non-HDL cholesterol) and anti-
atherogenic (HDL cholesterol), as well as other modiﬁable
factors of vascular-endothelial injury (visceral adiposity,
arterial hypertension, dysglycemia, etc.), complement the
wonderful pharmacological eﬀect of statins [70].
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